# Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients

> **NCT03190239** · PHASE2 · WITHDRAWN · sponsor: **Xinqiao Hospital of Chongqing**

## Conditions studied

- Advanced Non-squamous Non-small-cell Lung Cancer

## Interventions

- **DRUG:** Apatinib
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT03190239
- **Lead sponsor:** Xinqiao Hospital of Chongqing
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-07-15
- **Primary completion:** 2020-07-30
- **Final completion:** 2020-07-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** abandon
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03190239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03190239, "Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03190239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*